PiperJaffray Downgrades Novavax to Neutral with Price Target $1.00

Brokerage firm PiperJaffray Downgrades its rating on Novavax(NASDAQ:NVAX). In a research note issued to the investors, the brokerage major Lowers the price-target to $1.00 per share. The shares have been rated Neutral. Previously, the analysts had a Overweight rating on the shares. The rating by PiperJaffray was issued on Sep 16, 2016.

In a different note, On Sep 16, 2016, JP Morgan said it Downgrades its rating on Novavax. The shares have been rated ‘Neutral’ by the firm. On Jul 28, 2016, Citigroup said it Maintains its rating on Novavax. In the research note, the firm Raises the price-target to $10.00 per share. The shares have been rated ‘Buy’ by the firm.

Novavax (NVAX) made into the market gainers list on Thursdays trading session with the shares advancing 10.82% or 0.21 points. Due to strong positive momentum, the stock ended at $2.15, which is also near the day’s high of $2.25. The stock began the session at $2.24 and the volume stood at 8,51,52,254 shares. The 52-week high of the shares is $10.7 and the 52 week low is $1.16. The company has a current market capitalization of $583 M and it has 27,11,87,650 shares in outstanding.

Novavax(NVAX) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.50M. Analysts had an estimated revenue of $8.03M. Earnings per share were $-0.29. Analysts had estimated an EPS of $-0.25.

Several Insider Transactions has been reported to the SEC. On Aug 2, 2016, Barclay A Phillips (CFO) purchased 422 shares at $4.29 per share price.Also, On Jun 7, 2016, Gary C Evans (director) sold 18,998 shares at $6.50 per share price.On Feb 1, 2016, John Trizzino (SVP, Commercial Operations) purchased 5,855 shares at $3.63 per share price, according to the Form-4 filing with the securities and exchange commission.

Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *